Govt Issues Export Guidelines for Doxycycline 100 mg Dispersible Tablets
New Delhi: The Directorate General of Foreign Trade (DGFT), under the Ministry of Commerce and Industry, has issued Public Notice No. 03/2025-26 dated April 24, 2025, formally notifying a new Standard Input Output Norm (SION) under the Chemicals & Allied Products (Product Group A) for Doxycycline 100 mg Dispersible Tablets.
The SION, now listed under serial number A-3685, has been introduced to streamline export processes and establish standardized input-output parameters for the formulation. The notice has been issued in exercise of powers conferred under Paragraph 1.03 of the Foreign Trade Policy, 2023, as amended from time to time.
Key Inputs and Output Norms as per DGFT SION A-3685:
Export Product | Qty. | Sl. No. | Import Items | Qty. allowed. |
Doxycycline 100 mg. Dispersible Tablets (Eq. to Anhydrous Doxycycline 100 mg.) | 1 Number Tablet | I | Doxycycline Monohydrate U.S.P/B.P | 106.13 mg. |
According to the DGFT notification, “The following Standard Input Output Norms (SION) is included in the Handbook of Procedures, 2023 under Appendix 4B, as under:”
The SION is likely to boost competitiveness for Indian exporters catering to global antibiotic markets, particularly in low- and middle-income countries where demand for affordable dispersible antibiotic tablets remains strong.
The notification has come into immediate effect from the date of issue.
To view the official DGFT public notice, click on the link below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.